Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.

[1]  P. Hoskin,et al.  GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  C. Ménard,et al.  Boosting imaging defined dominant prostatic tumors: a systematic review. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  D. Baltas,et al.  A gEUD-based inverse planning technique for HDR prostate brachytherapy: feasibility study. , 2013, Medical physics.

[4]  Y. Lievens,et al.  Health economic controversy and cost-effectiveness of proton therapy. , 2013, Seminars in radiation oncology.

[5]  M. Stock,et al.  Is there an advantage in designing adapted, patient-specific PTV margins in intensity modulated proton beam therapy for prostate cancer? , 2013, International journal of radiation oncology, biology, physics.

[6]  M. Zelefsky,et al.  Secondary cancers after intensity‐modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause‐specific survival outcomes according to the initial treatment intervention , 2012, BJU international.

[7]  Tohru Okada,et al.  Carbon ion radiotherapy in advanced hypofractionated regimens for prostate cancer: from 20 to 16 fractions. , 2012, International journal of radiation oncology, biology, physics.

[8]  M. Zelefsky,et al.  Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[9]  C. Kirisits,et al.  Comparison between external beam radiotherapy (70 Gy/74 Gy) and permanent interstitial brachytherapy in 890 intermediate risk prostate cancer patients. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  J. Ciezki,et al.  Long-Term (10-Year) Gastrointestinal and Genitourinary Toxicity after Treatment with External Beam Radiotherapy, Radical Prostatectomy, or Brachytherapy for Prostate Cancer , 2012, Prostate Cancer.

[11]  Adam P Dicker,et al.  A novel curvilinear approach for prostate seed implantation. , 2012, Medical physics.

[12]  P. Hoskin,et al.  High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence. , 2012, International journal of radiation oncology, biology, physics.

[13]  M. Stock,et al.  IGRT induced dose burden for a variety of imaging protocols at two different anatomical sites. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  Adam P Dicker,et al.  Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group , 2012, BJU international.

[15]  Søren M Bentzen,et al.  Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? , 2011, International journal of radiation oncology, biology, physics.

[16]  K. Nihei,et al.  Multi-institutional Phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities. , 2011, International journal of radiation oncology, biology, physics.

[17]  Jette Borg,et al.  Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with d(90) ≥180 Gy. , 2010, International journal of radiation oncology, biology, physics.

[18]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[19]  M. V. van Herk,et al.  Urinary obstruction in prostate cancer patients from the Dutch trial (68 Gy vs. 78 Gy): relationships with local dose, acute effects, and baseline characteristics. , 2010, International journal of radiation oncology, biology, physics.

[20]  P. Levendag,et al.  Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  Kyounghwa Bae,et al.  Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Deasy,et al.  Radiation dose-volume effects in radiation-induced rectal injury. , 2010, International journal of radiation oncology, biology, physics.

[23]  H. Ishikawa,et al.  Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer. , 2006, International journal of radiation oncology, biology, physics.

[24]  D. Brenner.  Fractionation and late rectal toxicity. , 2004, International journal of radiation oncology, biology, physics.

[25]  H. Akaza,et al.  Phase I/II clinical trials of carbon ion therapy for prostate cancer , 2004, The Prostate.

[26]  Joseph O Deasy,et al.  CERR: a computational environment for radiotherapy research. , 2003, Medical physics.

[27]  L. Potters,et al.  Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. , 2002, International journal of radiation oncology, biology, physics.

[28]  O Jäkel,et al.  Treatment planning for heavy-ion radiotherapy: physical beam model and dose optimization. , 2000, Physics in medicine and biology.

[29]  A. Zietman,et al.  Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis. , 2012, International journal of radiation oncology, biology, physics.

[30]  J. Hendry,et al.  Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. , 2012, International journal of radiation oncology, biology, physics.

[31]  Zuofeng Li,et al.  Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[32]  L. Budäus,et al.  Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. , 2012, European urology.

[33]  R. Stock,et al.  Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. , 2001, International journal of radiation oncology, biology, physics.